Tumor antigens recognized by T cells

被引：470

作者：

Boon, T ^{[1
]}

Coulie, PG ^{[1
]}

VandenEynde, B ^{[1
]}

机构：

[1] UNIV CATHOLIQUE LOUVAIN,CELLULAR GENET UNIT,B-1200 BRUSSELS,BELGIUM

来源：

IMMUNOLOGY TODAY | 1997年 / 18卷 / 06期

关键词：

D O I：

10.1016/S0167-5699(97)80020-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A large number of human tumor-specific antigens have been identified. Here, Thierry Boon and colleagues explain that the priority now is to demonstrate that immunization against them is clinically valuable.

引用

页码：267 / 268

页数：2

共 15 条

[1] Phenotypic analysis of antigen-specific T lymphocytes [J].

Altman, JD ;

Moss, PAH ;

Goulder, PJR ;

Barouch, DH ;

McHeyzerWilliams, MG ;

Bell, JI ;

McMichael, AJ ;

Davis, MM .

SCIENCE, 1996, 274 (5284) :94-96

[2] The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation [J].

DeSmet, C ;

DeBacker, O ;

Faraoni, I ;

Lurquin, C ;

Brasseur, F ;

Boon, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7149-7153

[3] IDENTIFICATION OF AN IMMUNODOMINANT PEPTIDE OF HER-2/NEU PROTOONCOGENE RECOGNIZED BY OVARIAN TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTE LINES [J].

FISK, B ;

BLEVINS, TL ;

WHARTON, JT ;

IOANNIDES, CG .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (06) :2109-2117

[4] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].

Hahne, M ;

Rimoldi, D ;

Schroter, M ;

Romero, P ;

Schreier, M ;

French, LE ;

Schneider, P ;

Bornand, T ;

Fontana, A ;

Lienard, D ;

Cerottini, JC ;

Tschopp, J .

SCIENCE, 1996, 274 (5291) :1363-1366

[5] Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells [J].

Hsu, FJ ;

Benike, C ;

Fagnoni, F ;

Liles, TM ;

Czerwinski, D ;

Taidi, B ;

Engleman, EG ;

Levy, R .

NATURE MEDICINE, 1996, 2 (01) :52-58

[6] Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor [J].

Ikeda, H ;

Lethe, B ;

Lehmann, F ;

VanBaren, N ;

Baurain, JF ;

DeSmet, C ;

Chambost, H ;

Vitale, M ;

Moretta, A ;

Boon, T ;

Coulie, PG .

IMMUNITY, 1997, 6 (02) :199-208

[7] Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [J].

Marchand, M ;

Weynants, P ;

Rankin, E ;

Arienti, F ;

Belli, F ;

Parmiani, G ;

Cascinelli, N ;

Bourlond, A ;

Vanwijck, R ;

Humblet, Y ;

Canon, JL ;

Laurent, C ;

Naeyaert, JM ;

Plagne, R ;

Deraemaeker, R ;

Knuth, A ;

Jager, E ;

Brasseur, F ;

Herman, J ;

Coulie, PG ;

Boon, T .

INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (06) :883-885

[8] INFLUENCE OF INTERLEUKIN-12 ON P53 PEPTIDE VACCINATION AGAINST ESTABLISHED METH-A SARCOMA [J].

NOGUCHI, Y ;

RICHARDS, EC ;

CHEN, YT ;

OLD, LJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (06) :2219-2223

[9] HUMAN NEOPLASMS ELICIT MULTIPLE SPECIFIC IMMUNE-RESPONSES IN THE AUTOLOGOUS HOST [J].

SAHIN, U ;

TURECI, O ;

SCHMITT, H ;

COCHLOVIUS, B ;

JOHANNES, T ;

SCHMITS, R ;

STENNER, F ;

LUO, GR ;

SCHOBERT, I ;

PFREUNDSCHUH, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (25) :11810-11813

[10] Recognition of BCR-ABL positive leukemic blasts by human CD4(+)T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide [J].

tenBosch, GJA ;

Joosten, AM ;

Kessler, JH ;

Melief, CJM ;

Leeksma, OC .

BLOOD, 1996, 88 (09) :3522-3527

← 1 2 →